UPC APP 3214/2025

Jan 21, 2025·EP3666797 · ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

Case details: Status
Written Phase
Action
Generic
Category
File-access requests (R. 262.1(b))
Parties: Claimants
Name withheld (GDPR)
Representatives
Sture Rygaard
Respondents
Sanofi-Aventis Deutschland GmbHOperating co.
Amgen Inc.Operating co.
Dehns
Name withheld (GDPR)
Representatives
Daniel Wise-Carpmaels & Ransford
Koen Bijvank-Brinkhof
John Somerton-Dehns
Oswin Ridderbusch
Division: Munich CD
Judges: Ulrike Voß
András Kupecz
Casper Struve
Technology: Chemistry
Biotechnology · Pharmaceuticals
Language: English
EPO Opposition: Sanofi-Aventis Deutschland GmbHAdmissible2023-11-10
REGENERON PHARMACEUTICALS, INC.Admissible2024-02-19
Sanofi-Aventis Groupe S.A.Withdrawn2023-11-10
Sanofi Winthrop Industrie S.A.Withdrawn2023-11-10

How this compares

How long the court takes to reach a first decision.

	Median days to first decision
All UPC	124
Munich CD	Locked
Judge Ulrike Voß	Locked
Judge András Kupecz	Locked
Judge Casper Struve	Locked

At the UPC: Sanofi Group (33 cases)

Related cases

More cases: Munich CD·2025

Documents

Document title	Date	Public
preliminary order re representation	2025-02-18	Not public
US Delaware District Court Memorandum Order	2025-02-11	Not public
2025.02.11 Response to Rule 262.1(b) RoP - signed	2025-02-11	Not public
2025.02.11 Response to Rule 262.1(b) RoP - signed	2025-02-11	Not public
US Delaware District Court Memorandum Order	2025-02-11	Not public
2025.02.11 Response to Rule 262.1(b) RoP - signed	2025-02-11	Not public
US Delaware District Court Memorandum Order	2025-02-11	Not public
Reply to Rule 262.1 (b)	2025-02-11	Not public
PO consulting parties	2025-01-28	Not public
Application for access to files RoP art. 262 b)	2025-01-21	Not public